Construction and immunogenicity of recombinant adenovirus co-expressing the GP5 and M protein of porcine reproduction and respriratory syndrome virus in mice.
- Author:
Tao YUN
1
;
Zheng NI
;
Bin YU
;
Liu CHEN
;
Jionggang HUA
;
Genrong WANG
;
Guangqing LIU
Author Information
1. Research Institute of Virology & Biotechnology, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China.
- Publication Type:Journal Article
- MeSH:
Adenoviridae;
genetics;
metabolism;
Animals;
Female;
Immunization;
Mice;
Mice, Inbred BALB C;
Recombinant Fusion Proteins;
genetics;
immunology;
metabolism;
Swine;
Vaccines, Synthetic;
immunology;
Viral Envelope Proteins;
genetics;
immunology;
metabolism;
Viral Matrix Proteins;
genetics;
immunology;
metabolism;
Viral Vaccines;
immunology
- From:
Chinese Journal of Biotechnology
2009;25(4):488-495
- CountryChina
- Language:Chinese
-
Abstract:
FMDV 2A peptide was introduced as a linker between GP5 and M protein of porcine reproduction and respiratory syndrome virus (PRRSV) to allow automatic self-cleavage the polyproteins. This strategy simultaneously displayed the neutralizing action of GP5 protein and cell-mediated immunity of M protein. We put them into the expression cassette of adenovirus vector. The results of RT-PCR, IFA and Western blotting showed that GP5 and M protein were not only expressed correctly, but also self-cleavaged and assemble heterodimers formation. To detect the advantages of rAd-GP5-2A-M, we also constructed some other recombinant adenoviruses (rAd-GP5, rAd-M and rAd-GP5-M) as control. After inoculated subcutaneously into BALB/c mice, the four recombinant adenoviruses can induce PRRSV-specific antibodies and cell-mediated immune response, but the level of humoral and cell-mediated immune response against PRRSV induced by rAd-GP5-2A-M is the strongest among the four recombinant adenoviruses. All of these suggested that it is possible to develop one multi-gene engineering vaccine utilizing FMDV 2A peptide, and also provided a novel strategy for developing other viral disease vaccine.
